IP Library Granted Patent US 11,857,646
Granted Patent B2
US 11,857,646 · App. 17/325,173 · Granted Jan 2, 2024

Methods for making ultrasound contrast agents

Inventors: Simon P. Robinson (Stow, MA); Robert W. Siegler (Bedford, MA); Nhung Tuyet Nguyen (Westford, MA); David C. Onthank (Groton, MA); Tarakeshwar Vishwanath Anklekar (Billerica, MA); Charles Chester Van Kirk (Beverly, MA)
Assignee: Lantheus Medical Imaging, Inc.
A61K49/223A61B8/481A61K49/226A61K49/227C07F9/09C07F9/106
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,857,646
App. No.
17/325,173
Granted
Jan 2, 2024
Kind
B2
Abstract

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Claims (33)

1. A method for preparing a phospholipid suspension useful for preparing lipid-encapsulated gas microspheres comprising

forming a phospholipid solution that comprises (a) a DPPA, DPPC, and MPEG5000-DPPE phospholipid blend and propylene glycol, and (b) calcium and/or magnesium at a combined concentration of less than 0.7 ppm, wherein the phospholipid blend is formed in the presence of one or two but not all three of methanol, toluene and methyl t-butyl ether (MTBE), and

combining the phospholipid solution with an aqueous solution to form a phospholipid suspension.

2. The method of claim 1 , wherein the MPEG5000-DPPE comprises calcium and/or magnesium at a combined concentration of less than 115 ppm.

3. The method of claim 2 , wherein the phospholipid blend is formed in the presence of methanol.

4. The method of claim 2 , wherein the phospholipid blend is formed in the presence of toluene.

5. The method of claim 2 , wherein the phospholipid blend is formed in the presence of methanol and toluene.

6. The method of claim 2 , wherein the phospholipid blend is formed in the presence of MTBE.

7. The method of claim 1 , wherein the phospholipid blend is formed in the presence of methanol.

8. The method of claim 1 , wherein the phospholipid blend is formed in the presence of toluene.

9. The method of claim 1 , wherein the phospholipid blend is formed in the presence of methanol and toluene.

10. The method of claim 1 , wherein the phospholipid blend is formed in the presence of MTBE.

11. The method of claim 1 , wherein DPPA, DPPC and MPEG5000-DPPE are present in the phospholipid solution in a mole % ratio of 10 to 82 to 8 (10:82:8).

12. The method of claim 1 , wherein DPPA comprises calcium and/or magnesium at a combined concentration of less than 780 ppm, DPPC comprises calcium and/or magnesium at a combined concentration of less than 90 ppm, and propylene glycol comprises calcium and/or magnesium at a combined concentration of less than 0.7 ppm.

13. A method of ultrasound contrast imaging a subject comprising

preparing a phospholipid suspension according to claim 1 ,

activating the phospholipid suspension with a perfluorocarbon gas to form lipid-encapsulated gas microspheres,

administering the lipid-encapsulated gas microspheres to a subject, and

obtaining an ultrasound image of the subject.

14. The method of claim 13 , wherein the perfluorocarbon gas is perfluoropropane gas.

15. The method of claim 13 , wherein DPPA, DPPC and MPEG5000-DPPE are present in the phospholipid suspension in molar percentages of 5-15%, 77-90% and 5-15%, respectively.

16. The method of claim 13 , wherein the phospholipid suspension further comprises water, propylene glycol, one or more salts, and one or more buffers.

17. A method for preparing a phospholipid suspension useful for preparing lipid-encapsulated gas microspheres comprising

forming a phospholipid solution by individually combining DPPA, DPPC, and MPEG5000-DPPE with propylene glycol, wherein the phospholipid solution comprises calcium and/or magnesium at a combined concentration of less than 0.7 ppm, and

combining the phospholipid solution with an aqueous solution to form a phospholipid suspension.

18. A method of ultrasound contrast imaging a subject comprising

preparing a phospholipid suspension according to claim 17 ,

activating the phospholipid suspension with a perfluorocarbon gas to form lipid-encapsulated gas microspheres,

administering the lipid-encapsulated gas microspheres to a subject, and

obtaining an ultrasound image of the subject.

19. The method of claim 18 , wherein the perfluorocarbon gas is perfluoropropane gas.

20. The method of claim 18 , wherein DPPA, DPPC and MPEG5000-DPPE are present in the phospholipid suspension in molar percentages of 5-15%, 77-90% and 5-15%, respectively.

21. The method of claim 18 , wherein the phospholipid suspension further comprises water, propylene glycol, one or more salts, and one or more buffers.

Assignments (3)
SECURITY INTEREST Recorded Dec 17, 2025
From: LANTHEUS MEDICAL IMAGING, INC.; PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A., AS COLLATERAL AGENT, NATIONAL BANKING ASSOCIATION
Reel/Frame 073250/0201 →
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2021
From: ROBINSON, SIMON P.; SIEGLER, ROBERT W.; NGUYEN, NHUNG TUYET; ONTHANK, DAVID C.; VAN KIRK, CHARLES CHESTER; ANKLEKAR, TARAKESHWAR VISHWANATH
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 057766/0683 →
Cited By (1)
US 12,296,029